Now accepting nominations for the FiercePharma Marketing Awards
Applications are due Friday, September 13th. Submit your nominations today.
Glenmark hopes to raise cash from selling drugs outside of its focus therapeutic areas and from finding new investors for its API and innovation spinoffs.
Sun's Shanghvi took a 99% pay cut last year. Dr. Reddy's copies of Copaxone and NuvaRing were rejected by the FDA. Natco eyes China amid hardship.
There are five or six potential deals similar to Takeda's mooted European sale Stada could go after, CEO Peter Goldschmidt said.
Sun Pharma chief Dilip Shanghvi snared only $3,690 in 2018 pay—including a 1.5-cent salary—as investors questioned its management practices.
A judge orders Allergan to turn over Botox production details; A U.S. senator urges the FDA to run surprise inspections; the FDA approves Daiichi's cancer…
The Japanese drugmaker has snatched its first U.S. cancer nod since 2011 amid a big pivot from primary care to oncology.
Original Takeda employees alleged faced unfair changes in their roles and got different incentive plans during the integration.
CDMO Fujifilm Diosynth has acquired from Biogen a biologics production facility in Denmark with about 800 employees.
Takeda's quarterly margin hits 32.4%; the FDA slaps a Dr. Reddy's API plant with a Form 483; Strides Pharma enters China through a joint venture.
Takeda's been cutting costs on one hand and raising cash on the other to pay off its Shire deal debt—and so far, it's on track to hit those goals.